Addressing the selectivity and toxicity of antiviral nucleosides

JY Feng - Antiviral Chemistry and Chemotherapy, 2018 - journals.sagepub.com
JY Feng
Antiviral Chemistry and Chemotherapy, 2018journals.sagepub.com
Nucleoside and nucleotide analogs have played significant roles in antiviral therapies and
are valued for their impressive potency and high barrier to resistance. They have been
approved for treatment of herpes simplex virus-1, HIV, HBV, HCV, and influenza, and new
drugs are being developed for the treatment of RSV, Ebola, coronavirus MERS, and other
emerging viruses. However, this class of compounds has also experienced a high attrition
rate in clinical trials due to toxicity. In this review, we discuss the utility of different …
Nucleoside and nucleotide analogs have played significant roles in antiviral therapies and are valued for their impressive potency and high barrier to resistance. They have been approved for treatment of herpes simplex virus-1, HIV, HBV, HCV, and influenza, and new drugs are being developed for the treatment of RSV, Ebola, coronavirus MERS, and other emerging viruses. However, this class of compounds has also experienced a high attrition rate in clinical trials due to toxicity. In this review, we discuss the utility of different biochemical and cell-based assays and provide recommendations for assessing toxicity liability before entering animal toxicity studies.
Sage Journals